Press Releases

Date	Title
February 14, 2022	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial launch planning underway Financed through the anticipated approval of the ONS-5010 BLA ISELIN, N.J. , Feb.
February 10, 2022	Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference Live video webcast presentation on Friday, February 18th at 10:40 AM ET ISELIN, N.J. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in
February 8, 2022	Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations Joel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and account management ISELIN, N.J. , Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved
February 2, 2022	Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival ISELIN, N.J. , Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that members of management will be
January 25, 2022	Outlook Therapeutics Provides a Corporate Update and Business Outlook Outlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarter ONS-5010 / LYTENAVA™ (bevacizumab-vikg) expected to receive, if approved, 12 years of regulatory exclusivity in the U.S.
January 19, 2022	Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference Live video webcast presentation on Tuesday, January 25th at 3:00 PM ET ISELIN, N.J. , Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in
January 4, 2022	Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference ISELIN, N.J. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C.
December 22, 2021	Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update Positive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2021 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial for wet age-related macular degeneration (wet AMD) Recent financing
December 15, 2021	Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia Francesco Bandello, MD, FEBO, will present Phase 3 pivotal safety and efficacy data from the NORSE TWO registration trial ISELIN, N.J. , Dec. 15, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved
December 9, 2021	Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress Suber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial ISELIN, N.J. , Dec. 09, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of